This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2022.
Program Description
Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are subtypes of B-cell non-Hodgkin lymphomas, which have similar treatment recommendations. Therapy options include observation, systemic cytotoxic chemotherapy, anti-CD20−targeted therapy, and oral therapies, with the treatment landscape changing to include more recently developed CD-19-directed therapies and antibody-drug conjugates. Therapy decisions are based on patient- and disease-specific factors, including genetic and molecular features. As pharmacists are involved in caring for patients with FL and MZL, they need to be familiar with recent clinical data and guideline recommendations. This program will feature case discussions from expert faculty, highlighting clinical pearls and the latest updates in practice.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 15, 2022
Expiration date: April 15, 2023
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Employ the most recent clinical data and guideline recommendations to personalize treatment for patients with follicular lymphoma (FL) or marginal zone lymphoma (MZL)
- Differentiate oral oncolytics, CD19-directed therapies, and bispecific antibodies for the treatment of FL and MZL based on pharmacology and adverse effect profiles
- Determine strategies to mitigate adverse effects and optimize care for patients receiving treatment with oral oncolytics, CD19-directed therapy, or bispecific antibodies
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
